Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours

BACKGROUND: TAS-102 consists of α, α, α-trifluorothymidine (TFT) and an inhibitor of thymidine phosphorylase (TPI). We conducted a dose-escalation phase I study in Japanese patients with advanced solid tumours. METHODS: TAS-102 was administered twice daily on days 1–5 and days 8–12 in a 28-day cycle...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, T, Ohtsu, A, Yoshino, T, Boku, N, Onozawa, Y, Fukutomi, A, Hironaka, S, Koizumi, W, Sasaki, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405214/
https://www.ncbi.nlm.nih.gov/pubmed/22735906
http://dx.doi.org/10.1038/bjc.2012.274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405214/
https://www.ncbi.nlm.nih.gov/pubmed/22735906
http://dx.doi.org/10.1038/bjc.2012.274

Ejemplares similares